ArticleCancer management and research2025
MRI Radiomics Predicts Early Biological Progression in a Preclinical Colon Cancer Model Following Mesenchymal Stem Cell Intervention.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preclinical models of stem cell-mediated analgesia and tissue repair: mechanisms, challenges, and future directions.Frontiers in cellular neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stem cell therapy is a potential approach for tumor treatment; however, its efficacy and safety remain incompletely controllable. Therefore, early prediction of tumor progression and therapeutic evaluation post-treatment to guide timely therapeutic adjustments is essential. Radiomics has recently been widely applied to assess tumor behavior and characteristics. This study aims to investigate the predictive value of MRI radiomics for therapeutic outcomes in the early stages of stem cell intervention in colon cancer. Methods: Subcutaneous tumor models were established by implanting CM38 colon cancer cells into the inguinal region of C57BL/6 mice. Bone marrow mesenchymal stem cells (MSCs) were intravenously injected via the tail vein within 24 hours. T1 weighted MRI scans were performed on day 7 to extract radiomic features, monitor tumor growth, and evaluate neovascularization (CD34) and proliferation (Ki67) via immunohistochemistry. An early-stage MRI radiomics model was constructed to predict colon cancer progression. Results: Tumors in the stem cell intervention group exhibited faster growth compared to the control group, though no significant volume difference was observed in the early phase. A total of 1162 radiomic features were extracted, with 17 strongly associated features (including texture features, first-order features texture and shape features) selected to build the prediction model. The final model demonstrated an AUC > 0.8 across both training and testing datasets. Conclusion: Intravenous MSC injection promotes the progression of subcutaneously implanted CM38 colon cancer. An MRI radiomics-based predictive model was successfully established, enabling early prediction of tumor progression post-intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.